Providers’ Payment And Delivery System Reforms Hold Both Threats And Opportunities For The Drug And Device Industries
Open Access
- 1 September 2012
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 31 (9) , 2059-2067
Abstract
For decades, medical device and specialty drug makers have produced a steady stream of breakthroughs and incremental improvements, from cancer therapies to orthopedic joint replacements, drug-eluting stents, and cardiac pacemakers. The advances were financed by a fragmented health care system that paid for whichever clinical technologies were favored by physicians without strong concern for cost. But now hospitals, health systems, insurers, and policy makers are embracing payment reforms that seek to control costs and foster uniformity in the adoption of new drugs and devices. This article explores payment reforms that will have an impact on the medical technology industry and describes opportunities for the industry to flourish in this new, more financially constrained landscape.Keywords
This publication has 17 references indexed in Scilit:
- Variability in Costs Associated with Total Hip and Knee Replacement ImplantsJournal of Bone and Joint Surgery, 2012
- Changing Physician Incentives For Cancer Care To Reward Better Patient Outcomes Instead Of Use Of More Costly DrugsHealth Affairs, 2012
- “Transparency Reports” on Industry Payments to Physicians and Teaching HospitalsJAMA, 2012
- Hospitals Respond To Medicare Payment Shortfalls By Both Shifting Costs And Cutting Them, Based On Market ConcentrationHealth Affairs, 2011
- How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of TreatmentHealth Affairs, 2010
- Aligning Physician and Hospital Incentives: The Approach at Hospital for Special SurgeryClinical Orthopaedics and Related Research, 2009
- Value-Based Purchasing For Medical DevicesHealth Affairs, 2008
- The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)Annals of Oncology, 2007
- Hospitals' Strategies for Orchestrating Selection of Physician Preference ItemsThe Milbank Quarterly, 2007
- Reimbursement for Cancer Treatment: Coverage of Off-Label Drug IndicationsJournal of Clinical Oncology, 2006